TransCode Starts Phase 2a Trial for TTX-MC138
BOSTON, May 27, 2026 TransCode Therapeutics, Inc., a clinical-stage biotechnology company focused on RNA-based cancer therapeutics, has announced the...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
BOSTON, May 27, 2026 TransCode Therapeutics, Inc., a clinical-stage biotechnology company focused on RNA-based cancer therapeutics, has announced the...
BRISBANE, CALIFORNIA, April 28, 2026 CareDx Inc. has announced a definitive agreement to acquire Naveris, marking a significant expansion...
BOSTON, April 16, 2026 Foundation Medicine, Inc. has announced a major expansion of its oncology diagnostics portfolio through the...
Fort Myers, Florida | April 13, 2026 NeoGenomics, Inc. has announced the presentation of multiple scientific abstracts at the...
AUSTIN, Texas — December 5, 2025 — Natera has announced the acquisition of Foresight Diagnostics, a precision oncology company...
Princeton, N.J., September 22, 2025 – Bristol Myers Squibb (BMS) announced that its investigational cereblon E3 ligase modulator (CELMoD™)...
Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection, presented new clinical performance data on its Foresight...
